9.16
전일 마감가:
$9.02
열려 있는:
$9.05
하루 거래량:
1.33M
Relative Volume:
0.46
시가총액:
$1.04B
수익:
-
순이익/손실:
$-294.51M
주가수익비율:
-2.573
EPS:
-3.56
순현금흐름:
$-244.42M
1주 성능:
+1.96%
1개월 성능:
-11.97%
6개월 성능:
-37.56%
1년 성능:
-78.09%
다인 테라 Stock (DYN) Company Profile
명칭
Dyne Therapeutics Inc
전화
(781) 786-8230
주소
1560 TRAPELO ROAD, WALTHAM
DYN을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
DYN
Dyne Therapeutics Inc
|
9.17 | 1.26B | 0 | -294.51M | -244.42M | -3.56 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
458.13 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
565.96 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
292.00 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
다인 테라 Stock (DYN) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-06-24 | 개시 | Bernstein | Mkt Perform |
2025-06-11 | 재개 | Raymond James | Outperform |
2025-06-02 | 재개 | Oppenheimer | Outperform |
2025-05-29 | 개시 | Evercore ISI | Outperform |
2025-03-12 | 개시 | BMO Capital Markets | Outperform |
2025-03-07 | 개시 | Scotiabank | Sector Outperform |
2024-12-13 | 개시 | Robert W. Baird | Outperform |
2024-11-26 | 개시 | RBC Capital Mkts | Outperform |
2024-10-24 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2024-05-21 | 재확인 | Chardan Capital Markets | Buy |
2024-04-30 | 개시 | Morgan Stanley | Overweight |
2024-02-20 | 개시 | H.C. Wainwright | Buy |
2023-02-27 | 업그레이드 | Raymond James | Outperform → Strong Buy |
2023-02-15 | 개시 | Oppenheimer | Outperform |
2023-01-26 | 개시 | Guggenheim | Buy |
2022-07-20 | 개시 | Chardan Capital Markets | Buy |
2022-07-12 | 개시 | Raymond James | Outperform |
2020-10-12 | 개시 | JP Morgan | Overweight |
2020-10-12 | 개시 | Jefferies | Buy |
2020-10-12 | 개시 | Piper Sandler | Overweight |
2020-10-12 | 개시 | Stifel | Buy |
모두보기
다인 테라 주식(DYN)의 최신 뉴스
Dyne Therapeutics Inc. Stock Analysis and ForecastGame-changing returns - PrintWeekIndia
What analysts say about Dyne Therapeutics Inc. stockFree Stock Chart Pattern Guide - PrintWeekIndia
Is Dyne Therapeutics Inc. a good long term investmentDynamic growth stocks - PrintWeekIndia
What drives Dyne Therapeutics Inc. stock priceAccelerated capital growth - jammulinksnews.com
Dyne Therapeutics (NASDAQ:DYN) Price Target Lowered to $9.00 at JPMorgan Chase & Co. - MarketBeat
Hedge Fund and Insider Trading News: Bill Ackman, Warren Buffett, Ray Dalio, Scott Bessent, Elliott Management, Citadel Investment Group, Balyasny Asset Management, Qualys Inc (QLYS), Dyne Therapeutics Inc (DYN), and More - Insider Monkey
Dyne Therapeutics (DYN) Stock Rises as CEO Increases Stake - GuruFocus
Dyne shares up after CEO buys stock (DYN:NASDAQ) - Seeking Alpha
Former Biogen VP Who Led SPINRAZA Success Joins Satellos to Advance DMD Treatment - Stock Titan
Dyne Therapeutics price target lowered to $41 from $46 at Evercore ISI - MSN
Strategic Confidence in Dyne Therapeutics: Insider Backing and Breakthroughs in Rare Disease Therapies - AInvest
How to Take Advantage of moves in (DYN) - news.stocktradersdaily.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - FinancialContent
Evercore ISI Analyst Lowers Dyne Therapeutics Price Target to $41, Maintains Outperform Rating - AInvest
RBC Capital Maintains a Buy Rating on Dyne Therapeutics (DYN) With a $25 PT - Yahoo Finance
Dyne Therapeutics (DYN) Sees Price Target Reduced by Evercore IS - GuruFocus
Dyne Therapeutics’ DYNE-251 Study Update: A Potential Game-Changer for Duchenne Muscular Dystrophy - TipRanks
RBC Capital Sticks to Their Buy Rating for Dyne Therapeutics (DYN) - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Dyne Therapeutics, Inc. (DYN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
(DYN) Trading Report - news.stocktradersdaily.com
Dyne Therapeutics, Inc. (DYN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ATTENTION DYN Shareholders: Lost Money on Dyne Therapeutics, Inc.? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Dyne Therapeutics, Inc. (DYN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Petri Dish: ProFound’s Novartis deal worth $750M, Dyne secures debt - The Business Journals
Dyne Therapeutics Announces Closing of Public Offering of Common - GuruFocus
Dyne Therapeutics' $230M Capital Injection: A Strategic Gamble in Rare Neuromuscular Disorders? - AInvest
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares - The Manila Times
Dyne Therapeutics Closes $230 Million Public Offering of Common Stock - Quiver Quantitative
Dyne Therapeutics Announces Closing of Public Offering of - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Dyne Therapeutics, Inc. (DYN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Dyne Therapeutics, Inc. (DYN) And Encourages Shareholders to Connect - ACCESS Newswire
Shareholders Alert: Investigation Into Dyne Therapeutics, Inc. (DYN)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Dyne Therapeutics (DYN) Launches $200 Million Public Offering - GuruFocus
Dyne Therapeutics slides on $200 mln equity raise - TradingView
Dyne Therapeutics, Inc. (DYN) Under Investigation for Potential Securities Law ViolationsContact Levi & Korsinsky Today - ACCESS Newswire
Dyne Therapeutics' $200M Stock Offering: Strategic Necessity or Shareholder Dilution? - AInvest
Fraud Investigation: Levi & Korsinsky Investigates Dyne Therapeutics, Inc. (DYN) on Behalf of Shareholders - ACCESS Newswire
Tesla, Progress Software, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - 富途牛牛
Dyne Therapeutics Prices Public Offering Of About 24.24 Mln Shares At $8.25/shr - Nasdaq
Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital - citybiz
Dyne Therapeutics Announces Proposed Public Offering of Common S - GuruFocus
Dyne Therapeutics stock falls after announcing $200 million share offering By Investing.com - Investing.com South Africa
Dyne Therapeutics stock falls after announcing $200 million share offering - Investing.com
Dyne Therapeutics Secures Up to $275 Million in Debt Financing From Hercules Capital - 富途牛牛
Potential Securities Fraud: Levi & Korsinsky Investigates Dyne Therapeutics, Inc. (DYN) - ACCESS Newswire
Dyne Therapeutics Secures $275M Loan Agreement - TipRanks
JonesTrading Initiates Coverage on Dyne Therapeutics With Buy Rating, $30 Price Target - MarketScreener
Dyne Therapeutics (DYN) Receives Buy Rating with Strong Growth Potential | DYN Stock News - GuruFocus
(DYN) Investment Report - news.stocktradersdaily.com
Dyne Therapeutics (DYN) Coverage Initiated by Bernstein with Moderate Outlook | DYN Stock News - GuruFocus
Ongoing Investigation Into Dyne Therapeutics, Inc. (DYN): Contact Levi & Korsinsky About Potential Fraud - ACCESS Newswire
다인 테라 (DYN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):